DEXCOM INC

San Diego, California, United States · Biotechnology

Dexcom develops, manufactures and distributes continuous glucose monitoring systems for diabetes management.

You have opened 5 full company profiles today. Create an account to keep reading them. Create an account

Key facts

Sep 14, 2026: Dexcom Appoints Jereme Sylvain as EVP, Chief Operating Officer and Chief Financial Officer
Sep 10, 2026: Dexcom Appoints Glenn S. Boehnlein as Director
Sep 10, 2026: SEC 8-K (5.02): On September 10, 2026, DexCom, Inc. appointed Jereme Sylvain as EVP, Chief Operating Officer and Chief Financial Officer, effective September 14, 2026. In connection with his promotion, on September 11, 2026, Mr. Sylvain signed an Offer Letter, establishing an annual base salary of $767,000 and an annual target bonus opportunity of 75% of his base salary. He will also continue to receive annual equity awards under the Company's Amended and Restated 2015 Equity Incentive Plan and be eligible for executive benefits under the Amended and Restated Severance & Change in Control Plan. This strategic appointment is significant as it consolidates key operational and financial leadership roles within the company, which may impact its operational efficiency and financial planning moving forward.

DEXCOM INC files 2 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.

Dexcom develops, manufactures and distributes continuous glucose monitoring systems for diabetes management.

DEXCOM INC is headquartered in San Diego, California, United States.

On Sep 14, 2026, Dexcom Appoints Jereme Sylvain as EVP, Chief Operating Officer and Chief Financial Officer

Yes. DEXCOM INC is publicly traded under the ticker DXCM.

Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy